Search

Your search keyword '"Chu, Tianqing"' showing total 12 results
Start Over Author "Chu, Tianqing" Publisher ame publishing company
12 results on '"Chu, Tianqing"'

1. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study

Author

Li, Jiaqi, primary, Huang, Kuofang, additional, Ji, Hao, additional, Qian, Jialin, additional, Lu, Haijiao, additional, Zhang, Yanan, additional, Russo, Alessandro, additional, Romero, Atocha, additional, Urbanska, Edyta Maria, additional, Tabbò, Fabrizio, additional, Zhao, Xiaoyu, additional, and Chu, Tianqing, additional

Published
2023
Full Text
View/download PDF

2. International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

Author

Zhou, Chengzhi, primary, Qin, Yinyin, additional, Zhao, Wei, additional, Liang, Zhenyu, additional, Li, Min, additional, Liu, Dan, additional, Bai, Li, additional, Chen, Yahong, additional, Chen, Yan, additional, Cheng, Yuan, additional, Chu, Tianqing, additional, Chu, Qian, additional, Deng, Haiyi, additional, Dong, Yuchao, additional, Fang, Wenfeng, additional, Fu, Xiuhua, additional, Gao, Beili, additional, Han, Yiping, additional, He, Yong, additional, Hong, Qunying, additional, Hu, Jie, additional, Hu, Yi, additional, Jiang, Liyan, additional, Jin, Yang, additional, Lan, Fen, additional, Li, Qiang, additional, Li, Shuben, additional, Li, Wen, additional, Li, Yaqing, additional, Liang, Wenhua, additional, Lin, Gen, additional, Lin, Xinqing, additional, Liu, Ming, additional, Liu, Xiaofang, additional, Liu, Xiaoju, additional, Liu, Zhefeng, additional, Lv, Tangfeng, additional, Mu, Chuanyong, additional, Ouyang, Ming, additional, Qin, Jianwen, additional, Ren, Shengxiang, additional, Shi, Huanzhong, additional, Shi, Minhua, additional, Su, Chunxia, additional, Su, Jin, additional, Sun, Dejun, additional, Sun, Yongchang, additional, Tang, Huaping, additional, Wang, Huijuan, additional, Wang, Kai, additional, Wang, Ke, additional, Wang, Mengzhao, additional, Wang, Qi, additional, Wang, Wei, additional, Wang, Xiaoping, additional, Wang, Yuehong, additional, Wang, Zhijie, additional, Wang, Zirui, additional, Wu, Lin, additional, Wu, Di, additional, Xie, Baosong, additional, Xie, Min, additional, Xie, Xiaohong, additional, Xie, Zhanhong, additional, Xu, Shufeng, additional, Xu, Xiaoman, additional, Yang, Xia, additional, Yin, Yan, additional, Yu, Zongyang, additional, Zhang, Jian, additional, Zhang, Jianqing, additional, Zhang, Jing, additional, Zhang, Xiaoju, additional, Zhang, Yingying, additional, Zhong, Diansheng, additional, Zhou, Qing, additional, Zhou, Xiangdong, additional, Zhou, Yanbin, additional, Zhu, Bo, additional, Zhu, Zhengfei, additional, Zou, Chenxi, additional, Zhong, Nanshan, additional, He, Jianxing, additional, Bai, Chunxue, additional, Hu, Chengping, additional, Li, Weimin, additional, Song, Yong, additional, Zhou, Jianying, additional, Han, Baohui, additional, Varga, Janos, additional, Barreiro, Esther, additional, Park, Hye Yun, additional, Petrella, Francesco, additional, Saito, Yuichi, additional, Goto, Taichiro, additional, Igai, Hitoshi, additional, Bravaccini, Sara, additional, Zanoni, Michele, additional, Solli, Piergiorgio, additional, Watanabe, Satoshi, additional, Fiorelli, Alfonso, additional, Nakada, Takeo, additional, Ichiki, Yoshinobu, additional, Berardi, Rossana, additional, Tsoukalas, Nikolaos, additional, Girard, Nicolas, additional, Rossi, Antonio, additional, Passaro, Antonio, additional, Hida, Toyoaki, additional, Li, Shiyue, additional, Chen, Liang’an, additional, and Chen, Rongchang, additional

Published
2023
Full Text
View/download PDF

3. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study

Author

Lin, Xinqing, primary, Deng, Haiyi, additional, Chu, Tianqing, additional, Chen, Likun, additional, Yang, Yilin, additional, Qiu, Guihuan, additional, Xie, Xiaohong, additional, Qin, Yinyin, additional, Liu, Ming, additional, Xie, Zhanhong, additional, Ouyang, Ming, additional, Li, Shiyue, additional, Song, Yong, additional, Petrella, Francesco, additional, Jakopovic, Marko, additional, Tsoukalas, Nikolaos, additional, Solli, Piergiorgio, additional, Goto, Taichiro, additional, Saito, Yuichi, additional, and Zhou, Chengzhi, additional

Published
2022
Full Text
View/download PDF

4. A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab

Author

Shen, Yinchen, primary, Li, Jiaqi, additional, Qiang, Huiping, additional, Lei, Yuqiong, additional, Chang, Qing, additional, Zhong, Runbo, additional, Stella, Giulia Maria, additional, Gelsomino, Francesco, additional, Kim, Yeon Wook, additional, Abed, Afaf, additional, Qian, Jialin, additional, and Chu, Tianqing, additional

Published
2022
Full Text
View/download PDF

5. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study

Author

Chu, Tianqing, primary, Zhang, Wei, additional, Zhang, Bo, additional, Zhong, Runbo, additional, Zhang, Xueyan, additional, Gu, Aiqin, additional, Shi, Chunlei, additional, Wang, Huimin, additional, Xiong, Liwen, additional, Lu, Jun, additional, Qian, Jianlin, additional, Zhang, Yanwei, additional, Dong, Yu, additional, Teng, Jiajun, additional, Gao, Zhiqiang, additional, Wang, Weimin, additional, Shen, Yinchen, additional, Nie, Wei, additional, Lim, Jeong Uk, additional, Mehta, Hiren J., additional, Neal, Joel W., additional, Lou, Yuqing, additional, Xu, Jianlin, additional, Zhong, Hua, additional, and Han, Baohui, additional

Published
2022
Full Text
View/download PDF

6. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study

Author

Qiang, Huiping, primary, Lei, Yuqiong, additional, Shen, Yinchen, additional, Li, Jiaqi, additional, Zhong, Hua, additional, Zhong, Runbo, additional, Zhang, Xueyan, additional, Chang, Qing, additional, Lu, Jiahuan, additional, Feng, Hui, additional, Zhu, Yan, additional, Addeo, Alfredo, additional, Banna, Giuseppe L., additional, Oh, In-Jae, additional, Qian, Jialin, additional, and Chu, Tianqing, additional

Published
2022
Full Text
View/download PDF

7. Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy

Author

Yu, Xin, primary, Li, Jiaqi, additional, Ye, Lingyun, additional, Zhao, Jing, additional, Xie, Mengqing, additional, Zhou, Juan, additional, Shen, Yinchen, additional, Zhou, Fei, additional, Wu, Yan, additional, Han, Chaonan, additional, Qian, Jialin, additional, Chu, Tianqing, additional, and Su, Chunxia, additional

Published
2021
Full Text
View/download PDF

9. Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors

Author

Cui, Shaohua, Xiong, Liwen, Lou, Yuqing, Shi, Huangping, Gu, Aiqin, Zhao, Yizhuo, Chu, Tianqing, Wang, Huimin, Zhang, Wei, Dong, Lili, and Jiang, Liyan

Subjects
Original Article
Abstract

Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have shown efficacy in patients with advanced lung cancers, survival predictors with these drugs have not been extensively investigated. This study was performed to explore factors that may predict progression-free survival (PFS) in Chinese lung adenocarcinoma patients treated with EGFR-TKIs.We retrospectively collected clinicopathologic data on 208 patients who received either gefitinib, erlotinib or icotinib, including the patients' EGFR mutation status and levels of six serum tumor markers [carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA125), squamous cell carcinoma antigen (SCC), cytokeratin-19 fragments (CYFRA21-1) and lactate dehydrogenase (LDH)]. Univariate and multivariate survival analyses were performed to identify independent prognostic factors associated with PFS.At the study cutoff date, 189 (90.9%) of the patients met the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria for progressive disease (PD), while 19 (9.1%) had stable disease (SD). The median PFS of the 208 patients was 12.4 months (95% CI, 11.0-13.8 months). In the multivariate analysis using a Cox proportional hazard model, a non-smoking history [hazard ratio (HR) =2.460; 95% CI, 1.484-4.079; P0.001], first-line treatment (HR =1.500; 95% CI, 1.062-2.119; P=0.021), and a high pretreatment serum level of CEA (HR =1.424; 95% CI 1.026-1.977; P=0.035) were found to be significant predictors of a longer PFS.In Chinese lung adenocarcinoma patients treated with EGFR-TKIs, a non-smoking history, first-line EGFR-TKIs treatment and a high serum level of CEA were independent predictors of a longer PFS along with an EGFR-activating mutation.

Published
2016

11. Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer

Author

Gu, Aiqin, Shi, Chunlei, Xiong, Liwen, Chu, Tianqing, Pei, Jun, and Han, Baohui

Subjects
Original Article
Abstract

To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC).A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity.A total of 89 patients were assessable. In patients treated with icotinib, the overall response rate (RR) was 36.0% (32/89), and the disease control rate (DCR) was 69.7% (62/89). RR and DCR were significantly improved in patients with adenocarcinoma versus non-adenocarcinoma (P0.05). The symptom improvement rate was 57.3% (51/89), and the main symptoms improved were cough, pain, chest distress, dyspnea, and Eastern Cooperative Oncology Group performance status. The main toxic effects were rash [30/89 (33.7%)] and diarrhea [15/89 (16.9%)]. The level of toxicity was typically low.The use of icotinib hydrochloride in the treatment of advanced NSCLC is efficacious and safe, and its toxic effects are tolerable.

Published
2013

12. Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Author

Cui S, Xiong L, Lou Y, Shi H, Gu A, Zhao Y, Chu T, Wang H, Zhang W, Dong L, and Jiang L

Abstract

Background: Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have shown efficacy in patients with advanced lung cancers, survival predictors with these drugs have not been extensively investigated. This study was performed to explore factors that may predict progression-free survival (PFS) in Chinese lung adenocarcinoma patients treated with EGFR-TKIs., Methods: We retrospectively collected clinicopathologic data on 208 patients who received either gefitinib, erlotinib or icotinib, including the patients' EGFR mutation status and levels of six serum tumor markers [carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA125), squamous cell carcinoma antigen (SCC), cytokeratin-19 fragments (CYFRA21-1) and lactate dehydrogenase (LDH)]. Univariate and multivariate survival analyses were performed to identify independent prognostic factors associated with PFS., Results: At the study cutoff date, 189 (90.9%) of the patients met the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria for progressive disease (PD), while 19 (9.1%) had stable disease (SD). The median PFS of the 208 patients was 12.4 months (95% CI, 11.0-13.8 months). In the multivariate analysis using a Cox proportional hazard model, a non-smoking history [hazard ratio (HR) =2.460; 95% CI, 1.484-4.079; P<0.001], first-line treatment (HR =1.500; 95% CI, 1.062-2.119; P=0.021), and a high pretreatment serum level of CEA (HR =1.424; 95% CI 1.026-1.977; P=0.035) were found to be significant predictors of a longer PFS., Conclusions: In Chinese lung adenocarcinoma patients treated with EGFR-TKIs, a non-smoking history, first-line EGFR-TKIs treatment and a high serum level of CEA were independent predictors of a longer PFS along with an EGFR-activating mutation.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results